Clinuvel to file new drug with FDA MELBOURNE, Australia

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Clinuvel to file new drug with FDA

MELBOURNE, Australia and NEW YORK, July 18, 2016 (GLOBE NEWSWIRE) -- Clinuvel Pharmaceuticals (ASX:CUV) (OTC:CLVLY) (XETRA: UR9 ) today announced that the US Food and Drug Administration (FDA) has concluded an initial review of data from the use of its drug SCENESSE® (afamelanotide 16mg) in the rare genetic disorder erythropoietic protoporphyria (EPP). The FDA has deemed Clinuvel’s clinical data package satisfactory for submitting a New Drug Application (NDA) and a pre-NDA meeting is now being scheduled.

“We welcome the FDA’s review and conclusion that the initial clinical datasets are sufficient for filing a NDA for SCENESSE®,” Clinuvel’s CEO, Dr Philippe Wolgen said. “This is the culmination of more than a decade of work in EPP, a debilitating and very specific disorder for which there is no other treatment.”

“Having received Fast Track designation for SCENESSE®, Clinuvel’s teams are now working closely with FDA to commence the NDA filing on a rolling basis. A request will also be made for Priority Review, which shortens the review time from 10 to six months, to expedite access to this much needed drug for US EPP patients,” Dr Wolgen said.

SCENESSE® in EPP EPP patients complain of burning under the skin, usually within minutes of exposure to bright lights, especially sunlight. The first sensation – phototoxicity – is the result of a chemical reaction taking place underneath patients’ skin which results in burns and damage of the tissues.

A first-in-class drug, SCENESSE® activates the pigment melanin in skin, providing a barrier which protects skin cells from light (photoprotection) while also acting as an anti-oxidant. SCENESSE® is delivered via a subcutaneous dissolving implant approximately the size of a grain of rice. Increased pigmentation of the skin appears after two days and lasts up to two months.

Five clinical trials of SCENESSE® in EPP showed the drug was well tolerated and could reduce the incidence and severity of EPP reactions to light (phototoxicity) in EPP. Trials also showed the drug could improve patients’ quality of life. Two phase III clinical trials, conducted in Europe and the USA, were published in the New England Journal of Medicine in 2015. 1

SCENESSE® was approved by the European Medicines Agency in 2014 and is now commercially available for the prevention of phototoxicity in adult EPP patients in a number of European countries. 2

FDA review The FDA conducted a four month review of datasets from Clinuvel’s clinical trial program, deeming the data satisfactory for formal NDA submission. SCENESSE® has previously been granted both Fast Track and orphan drug designations by the FDA for the treatment of EPP, recognising the severity of the disorder and potential of SCENESSE® to provide clinical benefit where no other therapy exists.

An FDA-initiated EPP workshop will take place on October 24 to learn more about the disease, and the effectiveness and safety of the proposed treatment. 3

“The FDA has shown a commitment to EPP patients and Clinuvel looks forward to expediting the availability of SCENESSE® in North America,” Dr Wolgen said. “This is a significant event for the patients for whom we work.”

1 Langendonk J et al (2015). Afamelanotide for Erythropoietic Protoporphyria. NEJM . 373(1):48-59.

2 SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in the orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug’s positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on Clinuvel’s website at www.clinuvel.com .

3 FDA Scientific Workshop: 24 October 2016: http://www.fda.gov/drugs/newsevents/ucm501389.htm .

About erythropoietic protoporphyria (EPP) Erythropoietic protoporphyria (EPP) is a rare genetic storage disorder that causes severe anaphylactic-like reactions to light (phototoxicity). Patients complain of burning under the skin, usually within minutes of exposure to bright lights, especially sunlight. The first sensation – phototoxicity – is the result of a chemical reaction taking place underneath patients’ skin which results in burns and damage of the tissues.

EPP symptoms can be acute, or delayed (subacute), most often expressed as generalised oedema, effusion in tissues and distortion of the skin. As little as a few minutes of light outdoors (even when it is overcast or transmitted through a window) or artificial light exposure may be sufficient to evoke EPP symptoms.

Phototoxicity is unresponsive to traditional pain and burn management techniques and patients can be incapacitated for days before reactions subside. Most patients withdraw from light exposure in order to manage their phototoxic symptoms.

About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX:CUV) (OTC:CLVLY) (XETRA: UR9 ) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the Clinuvel has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).

Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore.

For more information go to http://www.clinuvel.com .

SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd.

Forward-Looking Statements This release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 Lachlan.Hay@clinuvel.com Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 miles@cpc-pr.com Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 edagne@comstragroup.com Investor enquiries InvestorRelations@clinuvel.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 94

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading